Compare · LLY vs NEUP
LLY vs NEUP
Side-by-side comparison of Eli Lilly and Company (LLY) and Neuphoria Therapeutics Inc. (NEUP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and NEUP operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.33T, about 81945.4x NEUP ($16.2M).
- LLY has been more active in the news (31 items in the past 4 weeks vs 1 for NEUP).
- LLY has more recent analyst coverage (25 ratings vs 0 for NEUP).
- Company
- Eli Lilly and Company
- Neuphoria Therapeutics Inc.
- Price
- -
- -
- Market cap
- $1.33T
- $16.2M
- 1M return
- +23.23%
- -
- 1Y return
- +55.28%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 31
- 1
- Recent ratings
- 25
- 0
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest LLY
- President, Chair, and CEO Ricks David A gifted 23,538 shares (SEC Form 4)
- Treasury's Refunding Details Are Up Next as Five Large Companies Report Higher Revenue
- EVP, CS&PO & Pres. LRL Skovronsky Daniel gifted 119 shares, decreasing direct ownership by 0.07% to 159,953 units (SEC Form 4)
- EVP, GC & Secretary Hakim Anat sold $7,012,600 worth of shares (5,000 units at $1,402.52) as part of a pre-agreed trading plan (SEC Form 4)
- EVP & CFO Montarce Lucas converted options into 1,610 shares and covered exercise/tax liability with 678 shares, increasing direct ownership by 6% to 17,191 units (SEC Form 4)
- EVP & Pres., Mfg. Operations Hernandez Edgardo converted options into 2,530 shares and covered exercise/tax liability with 1,123 shares, increasing direct ownership by 3% to 47,490 units (SEC Form 4)
- EVP, Chief People Officer Dozier Eric converted options into 2,300 shares and covered exercise/tax liability with 1,019 shares, increasing direct ownership by 9% to 15,520 units (SEC Form 4)
- EVP & President, Card Met Hlth Custer Kenneth L. converted options into 3,220 shares and covered exercise/tax liability with 1,425 shares, increasing direct ownership by 18% to 11,935 units (SEC Form 4)
- EVP, President LLY Imm Brown Adrienne S converted options into 2,530 shares and covered exercise/tax liability with 1,099 shares, increasing direct ownership by 17% to 9,894 units (SEC Form 4)
- SEC Form 10-Q filed by Eli Lilly and Company
Latest NEUP
- SEC Form 8-K filed by Neuphoria Therapeutics Inc.
- SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.
- SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.
- SEC Form DEF 14A filed by Neuphoria Therapeutics Inc.
- SEC Form 10-K filed by Neuphoria Therapeutics Inc.
- SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.
- Neuphoria Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Changes in Control of Registrant, Regulation FD Disclosure, Financial Statements and Exhibits
- Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
- Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc
- Neuphoria Therapeutics Inc. filed SEC Form 8-K: Other Events